Biocept, Inc. BIOCQ
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -119.80% | -440.48% | -1,186.15% | -1,543.83% | -- |
| Total Depreciation and Amortization | 101.43% | -10.55% | 8.17% | -77.28% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -109.85% | -61.92% | -7.64% | 101.88% | -- |
| Change in Net Operating Assets | 183.25% | 536.18% | 1,181.15% | 392.90% | -- |
| Cash from Operations | -329.93% | -1,069.23% | -460.14% | -830.69% | -- |
| Capital Expenditure | 35.55% | 16.49% | 48.66% | 29.34% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 42.65% | 16.49% | 48.66% | 29.34% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -30.07% | -20.83% | -19.13% | 5.10% | -- |
| Issuance of Common Stock | -60.24% | -95.50% | -98.30% | -93.49% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -77.89% | -111.61% | -115.12% | -108.04% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -568.65% | -255.54% | -210.15% | -189.27% | -- |